Drugs / recombinant fowlpoxvirus
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT00332930 | Sep 2002 → Sep 2003 | HIV infectious disease | Kirby Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant fowlpoxvirus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00332930 ↗ |
| Known as | rFPV | “recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens” NCT00332930 ↗ |
| Modality | Vaccine | “therapeutic HIV vaccine candidate” NCT00332930 ↗ |
| Route | Intramuscular | “Vaccines will be delivered by intramuscular injection.” NCT00332930 ↗ |